Industry: Healthcare
Published Date: January-2023
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 247
Report ID: PMRREP31378
Worldwide revenue from the proteomics market was about US$35.9 Billion in 2024, with the global market estimated to surge ahead at a CAGR of 17.6% to reach a valuation of US$ 181.5 Billion by the end of 2033.
|
Proteomics Market Size (2024) |
US$35.9 Billion |
|
Projected Market Value (2033) |
US$181.5 Billion |
|
Global Market Growth Rate (2024-2033) |
17.6% |
|
Market Share of Top 5 Countries |
61.0% |
As assessed by Persistence Market Research, reagents and kits segment is expected to hold a largest market value of US$ 35.9 Billion by 2024. Overall, proteomics market sales account for approximately 6.0% revenue share in the global proteomics market, which was valued at around US$ 514.3 Billion at the end of 2023.
The global market for proteomics recorded a historic CAGR of 15.5% in the last 8 years from 2014 to 2022.
The high prevalence of target diseases and the rising demand for personalised medicines and advanced diagnostics in the treatment of targeted diseases are key factors promoting market growth. The market will grow as more focus is given to product usage in drug discovery, biomarker research, and clinical diagnostics for the detection and treatment of diseases.
As an example, in June 2022, researchers at the IISc (Indian Institute of Science) Bangalore developed a unique category of peptides or mini-proteins, and the researchers suggest it has the ability to kill viruses like SARS-CoV-2. The mini-proteins, according to a study that appeared in the journal Nature Chemical Biology, can also cluster virus particles to reduce their infectious potential and inhibit virus entry into human cells. Consequently, it is projected that the market will benefit from the growing research and development activities in drug designing sector.
Another factor projected to fuel market expansion is the increased prevalence of chronic diseases including cancer, cardiovascular disorders (CVDs), respiratory diseases, and others. For instance, according to Globocan, there were 10.6 million cancer-related deaths and 19.3 million new cases of cancer worldwide in December 2020. In the same manner, CVDs rank high among the world's leading causes of deaths. For instance, the WHO (2021) estimates that target diseases claim the lives of 41 million patients annually. As a result, the market is benefiting from the rising need for personalized medicines as a result of the rising prevalence of life-threatening diseases.
The global market is thus likely to show high growth over the coming years at a CAGR of 17.6% and reach a global market size of US$ 181.5 Billion by 2033.
“Technological Advancements & Increasing R&D Expenditure”
Manufacturers in the proteomics industry are concentrating on delivering new methods and equipment for disease diagnosis. This is anticipated to shed insight on the rapidity with which cancer and other viral and infectious diseases progress as well as the anticipated patient survival time. Companies like Agilent Technologies, Inc. have acknowledged using technology out-licensing strategies to concentrate on the creation of protein analysis products.
The absolute quantification of the protein-based diagnostic was made possible by the use of proteomic technology. The core proteomics services and other technologies, including as microarray, x-ray crystallography, spectroscopic procedures, chromatography, electrophoresis, and surface plasma resonance systems, have been the foundation of the proteomics market.
The increasing investment in R&D in the field of proteomics is a growth driver for the market. The National Institutes of Health (NIH) of the U.S. provided $37 billion for biomedical research. This funding was intended to aid in the study of the fundamental mechanisms through which diseases develop, the identification of biomarkers that indicate the presence of disease, or the identification of the gene or protein that causes the disease. The Novo Nordisk Foundation gave the University of Copenhagen a grant of up to $1.5 million to set up a mass spectrometry facility, which is an important stage in protein research. After the outbreak of the pandemic, the market gained traction rapidly.
Major players are essential in improving people' access to high-quality healthcare and medications in developing countries, which also broadens their economic prospects and they also work to increase economic opportunities through creating more jobs, influencing public policy, providing training, and investment. The pharmaceutical industry has a significant impact on the growth of economic opportunities in developing nations.
In the last few years, pharmaceutical companies have recorded excellent financial results. For instance, Thermo Fisher Scientific, Inc. achieved record profits last year, and future performance is predicted to be even better. The market will expand as there are more biopharmaceutical companies and more research and development is done.
“High Cost products/services and Lack of Skilled Professionals”
The development of new drugs, vaccinations, and disease diagnosis are all made possible by proteomics. This depends on the application of several technologies, including chromatography, protein fractionation systems, X-ray crystallography, spectroscopy, and reagent kits. Prices increased as a result of improvements in several instruments. For instance, mass spectrometers might cost anywhere between $20 Mn and $30 Mn. However, many consumers may not like to invest in such pricey products, especially for research organizations with restricted resources and funding.
Although proteomics has become a significant field of study in the life sciences sector, market growth is anticipated to be constrained by a lack of skilled workers and expertise in protein analysis procedures. It is now crucial that protein analysis techniques including X-ray crystallography, high-performance liquid chromatography (HPLC), and protein fractionation systems are carried out by qualified professionals as a result of technological and process improvements in biotechnology.
However, challenges impeding the expansion of the proteomics market include the increasing demand for large investments in upgrading protein synthesis equipment as well as the requirement for molecular method training. These considerations have resulted to a reported shortage of skilled workers who can cope to protein synthesis procedures and methodologies for proteomics service providers.
Why is the U.S. Proteomics Market Booming?
“Partnerships and Collaborations among Major Players”
The U.S. is expected to hold around 90.3% market share in the North America proteomics market at the end of 2024.
The growth in omics research, the desire for high-quality research equipment for data reproducibility, and focus on the development of individualized treatments are all factors that have contributed to U.S. dominance. Agreements and collaborations among major players in the nation are also helping to expand the market. One such example is the partnership between Symphogen and Thermo Fisher Scientific Inc. to create proven platform methods for the expedited characterisation and quality control of complex therapeutic proteins.
Will the Germany Be a Lucrative Market for the Manufacturers?
“Increased R&D Efforts”
With a 34.7% market share, Germany will hold a fair amount of share in Europe market at the end of 2024.
In Germany, the market is being driven by rising cancer research projects and government support. Germany will continue to prosper in the future due to the rise in the cancer rate and other serious diseases as well as the presence of large number of manufacturers of personalized medicines in the country.
How is Japan Emerging as a Prominent Market for Proteomics?
“Increased Government Support”
Japan is estimated to hold market share of about 53.8% of the East Asia market in 2024.
Proteomics market growth in Japan is anticipated to be driven by rising government initiatives to support research and development in genomics, bioinformatics, and proteomics during the forecast period.
One such event was the 13th international conference on Proteomics, Genomics, and Bioinformatics, which occurred in Tokyo, Japan, on May 10–11. The conference's theme was "Leading Edge Innovations in Life Sciences," and its main goal was to examine the most recent developments and innovative research approaches that may be used to promote proteomics and bioinformatics.
Which Component Segment is Driving Growth of the Global Market?
“Growing Demands for Reagents & Kits in research Settings”
Reagents & kits segment is expected to hold highest share of around 51.4% of the segment by the end of 2024.
During the anticipated period, the segment is expected to increase at fast pace. The extensive use of reagents & kits, chemicals, and strips for the analysis of different biological samples in academia, research labs, and other settings will lead to an increase in demand for reagents & kits, which will fuel the segment's growth. A new technique for protein analysis in a separation medium that spans significantly in all three spatial dimensions is provided by technical advancements in advanced methods, such as three-dimensional (3D)-gel electrophoresis.
Which Technology Segment is Driving Growth of the Global Market?
“Most Preferred Method for Assessing Gene Expression”
Microarray instruments segment is expected to hold highest share of around 27.1% of the segment by the end of 2024.
Microarray utilization is expected to rise across a range of applications, supporting market growth. For instance, microarray analysis has proven effective in antibiotic therapy because, in most situations, bacterial genomic DNA outgrows bacterial survival. Recently, the application of DNA-based microarrays has emerged as the preferred method for assessing gene expression. This is mostly due to factors like complexity and cost reduction, which increase the technology's accessibility and uniformity.
Which Application Segment is expected to Emerge as a Market Leader in the Future?
“Increasing Focus on Personalized Medications”
Drug discovery segment is expected to hold the larger share of about 39.0% by the end of 2024.
The expansion of this market can be attributed to the advancement of structure-based drug design, increased emphasis on developing personalized medicines, and increased investments in these fields. Proteomics technologies also provide a mechanism to demonstrate a medicine's potential early in the drug discovery process, saving pharmaceutical companies a large sum of money and ultimately helping patients and healthcare systems, which supports the segment's expansion.
Which End User Segment is expected to dominate the Market in Future?
“Plethora of Ongoing Projects in Research Institutions”
Research and academic institutions segment is expected to hold the larger share of about 51.5% by the end of 2024.
The need for molecular biology, enzymes and reagents & kits is being fueled by a surge in research and development activities, a range of ongoing proteome studies in the treatment of various life threatening diseases, and an increase in life science projects in the research and academic settings.
Major players in the global Proteomics market for proteomics are integrating novel technologies within their product portfolio. In order to increase their sales and market share, key players are adopting strategies such as mergers and acquisitions, as well as partnerships.
Key instances include:
Similarly, the team at Persistence Market Research has tracked recent developments related to companies in the melatonin API market, which are available in the full report.
|
Attribute |
Details |
|
Forecast Period |
2024-2033 |
|
Historical Data Available for |
2014-2022 |
|
Market Analysis |
USD Million for Value |
|
Key Countries Covered |
|
|
Key Market Segments Covered |
|
|
Report Coverage |
|
|
Key Companies’ Profile |
|
|
Customization & Pricing |
Available upon Request |
Component:
Technology:
Application:
End User:
Region:
To know more about delivery timeline for this report Contact Sales
The global market is anticipated to value around US$ 35.9 Billion at the end 2023.
Sales of the market are set to witness growth at a CAGR of 17.6% and be valued at around US$ 181.5 Billion by 2033.
Demand for the market increased at an 15.5% CAGR from 2014 to 2022.
U.S., China, Japan, Germany, and India accounted for the major share in the global market as of year 2022, holding around 61.0% market share.
The U.S. expected to account for around 31.8% share of the global market in 2023.
Latin America accounts for around 7.8% share of the global market in 2023.
Japan market is expected to hold a share of about 8.9% in the global proteomics market in 2023.
Germany is expected to hold about 17.1% of the global market share at the end of 2023.
The UK is expected to grow over a CAGR of 36.2%.
India is expected to grow over a CAGR of 25.9%.
